Kai Sun VIEW CLINICAL PROFILE

Kai Sun, MD, MS

Assistant Professor of Medicine, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Kai Sun received her Bachelor of Science in Medicine and Master of Science in Medicine from Medical College of Qingdao University. She completed her Internal Medicine Residency at Houston Methodist Hospital. Dr. Sun then completed Hematology and Oncology Fellowship at Houston Methodist Hospital and served as the Chief Fellow.

Description of Research

Dr Sun has a special interest in treating breast cancer. Her research interests include participation in clinical trials and research in obesity associated breast cancer.

Active Clinical Trials

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT05812807


A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

NCT05774951


A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996


The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

NCT04457596

Publications

5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer
Shao, J, Xu, Y, Olsen, RJ, Kasparian, S, Sun, K, Mathur, S, Zhang, J, He, C, Chen, SH, Bernicker, EH & Li, Z 2024, , Cells, vol. 13, no. 8, 715. https://doi.org/10.3390/cells13080715

Neighborhood Walkability Is Associated With Lower Burden of Cardiovascular Risk Factors Among Cancer Patients
Nwana, N, Makram, OM, Nicolas, JC, Pan, A, Gullapelli, R, Parekh, T, Javed, Z, Titus, A, Al-Kindi, S, Guan, J, Sun, K, Jones, SL, Maddock, JE, Chang, J & Nasir, K 2024, , JACC: CardioOncology, vol. 6, no. 3, pp. 421-435. https://doi.org/10.1016/j.jaccao.2024.03.009

The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer
O’Neill, CE, Sun, K, Sundararaman, S, Chang, JC & Glynn, SA 2024, , Frontiers in Physiology, vol. 15, 1358850. https://doi.org/10.3389/fphys.2024.1358850

P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab: Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023
Esmail, A, Xu, J, Burns, E, Gee, K, Wiechmann, C, Zhang, Y, Kieser, R, Gong, Z, Umoru, G, Shah, S, Sun, K, Heyne, K & Abdelrahim, M 2023, , Annals of Oncology, vol. 34, pp. S156. https://doi.org/10.1016/j.annonc.2023.04.465

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer: Cancers
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2023, . Cancers. https://doi.org/10.3390/cancers15010081

P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab: Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023
Esmail, A, Xu, J, Burns, E, Gee, K, Wiechmann, C, Zhang, Y, Kieser, R, Gong, Z, Umoru, G, Shah, S, Sun, K, Heyne, K & Abdelrahim, M 2023, , Annals of Oncology, vol. 34, pp. S156. https://doi.org/10.1016/j.annonc.2023.04.465, https://doi.org/10.1016/j.annonc.2023.04.465

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
Gee, K, Wiechmann, C, Burns, EA, Xu, J, Zhang, Y, Esmail, A, Crenshaw, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Bernicker, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1361-A1361. https://doi.org/10.1136/jitc-2023-SITC2023.1234

1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
Wiechmann, C, Gee, K, Burns, EA, Xu, J, Zhang, Y, Crenshaw, A, Esmail, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Efstathiou, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1360-A1360. https://doi.org/10.1136/jitc-2023-SITC2023.1233

451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab
Xu, J, Burns, EA, Gee, K, Wiechmann, C, Zhang, Y, Kieser, RB, Umoru, G, Shah, S, Sun, K, Abdelrahim, M & Esmail, A 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A502-A502. https://doi.org/10.1136/jitc-2023-SITC2023.0451

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer
Sun, K, Xu, Y, Mathur, S, Bernicker, EH & Chang, JC 2023, , Clinical Cancer Research.

Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review
Hodges, A, Sun, K, Sheu, TG & Bernicker, EH 2023, , Frontiers in Oncology, vol. 13, 1193503, pp. 1193503. https://doi.org/10.3389/fonc.2023.1193503

A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer
Guan, J, Sun, K, Guerrero, CA, Zheng, J, Xu, Y, Mathur, S, Teh, BS, Farach, A, Zhang, J, Butler, E, Pan, PY, Zsigmond, E, Mei, Z, Mejia, J, Chen, SH, Chang, JC & Bernicker, EH 2023, , International Journal of Radiation Oncology Biology Physics, vol. 118, no. 5, pp. 1531-1540. https://doi.org/10.1016/j.ijrobp.2023.08.044

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2022, , Cancers, vol. 15, no. 1. https://doi.org/10.3390/cancers15010081

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2022, , Cancers, vol. 15, no. 1, 81. https://doi.org/10.3390/cancers15010081, https://doi.org/10.3390/cancers15010081

480 Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies
Burns, EA, Xu, J, Kieser, R, Muhsen, I, Shah, S, Umoru, G, Mylavarapu, C, Zhang, Y, Crenshaw, A, Sun, K, Esmail, A, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J, Bernicker, E & Abdelrahim, M 2022, , J Immunother Cancer, vol. 10, no. Suppl 2, pp. A501. https://doi.org/10.1136/jitc-2022-SITC2022.0480

Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Yuan, X, Duan, Y, Xiao, Y, Sun, K, Qi, Y, Zhang, Y, Ahmed, Z, Moiani, D, Yao, J, Li, H, Zhang, L, Yuzhalin, AE, Li, P, Zhang, C, Badu-Nkansah, A, Saito, Y, Liu, X, Kuo, WL, Ying, H, Sun, SC, Chang, JC, Tainer, JA & Yu, D 2022, , Cancer Discovery, vol. 12, no. 7, pp. 1742-1759. https://doi.org/10.1158/2159-8290.CD-21-0900

Infections and their impact on patients on pembrolizumab-based therapies for head and neck cancer. Journal of Clinical Oncology
Zhang, Y, Xu, J, Muhsen, I, Burns, EA, Shah, SM, Umoru, G, Mylavarapu, C, Sun, K, Crenshaw, A, Esmail, A, Kieser, RB, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J & Abdelrahim, M 2022, , Journal of Clinical Oncology, vol. 40, no. 16_suppl, pp. 6035.

Outcomes of patients with advanced urothelial cancer who develop infection while on treatment with pembrolizumab. Journal of Clinical Oncology
Kieser, RB, Xu, J, Burns, EA, Muhsen, I, Shah, SM, Umoru, G, Mylavarapu, C, Sun, K, Zhang, Y, Crenshaw, A, Esmail, A, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J, Efstathiou, E, Bernicker, E & Abdelrahim, M 2022, , Journal of Clinical Oncology, vol. 40, no. 16_suppl, pp. 4573. https://doi.org/10.1200/JCO.2022.40.16_suppl.4573

Use of PEG-asparaginase in a case of Hepatosplenic ?d T-cell lymphoma with long-term remission after stem cell transplantation
Sun, K, Sanchez, CG, Pingali, SR & Iyer, S 2018, , ecancermedicalscience, vol. 12, 872. https://doi.org/10.3332/ecancer.2018.872

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
Sun, K, Kasparian, S, Iyer, S & Pingali, SR 2018, , ecancermedicalscience, vol. 12, 836. https://doi.org/10.3332/ecancer.2018.836

VIEW FULL PUBLICATIONS